CPP’s founders have pioneered the development and exploitation of key pathways implicated in cancer risk: polyamine synthesis and inflammation.

These two processes have long been implicated in cancer development but never successfully utilized—together—to exploit and treat cancer precursors until now. CPP believes that the best way to create and develop prevention therapy is to use a “combination” approach that incorporates the best scientific, drug development, and regulatory tools available.

In addition to product development, CPP is developing blood-based assays that allow for the selection of patients most likely to benefit from the agent and least likely to experience side effects from the treatment.

Finally, additional clinical and preclinical studies are ongoing for gastric cancer, pancreatic cancer, and early onset type I diabetes.

Risk Reduction Programs